444 related articles for article (PubMed ID: 28237354)
21. Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
Remon J; Pignataro D; Novello S; Passiglia F
Cancer Treat Rev; 2021 Apr; 95():102178. PubMed ID: 33743408
[TBL] [Abstract][Full Text] [Related]
22. Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement.
Wu J; Lin Y; He X; Yang H; He P; Fu X; Li G; Gu X
BMC Cancer; 2016 Aug; 16():599. PubMed ID: 27488371
[TBL] [Abstract][Full Text] [Related]
23. ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib.
Xu S; Wang W; Xu C; Li X; Ye J; Zhu Y; Ge T
BMC Cancer; 2019 Aug; 19(1):769. PubMed ID: 31382924
[TBL] [Abstract][Full Text] [Related]
24. Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Arnaoutakis K
N Engl J Med; 2015 Feb; 372(7):683. PubMed ID: 25671265
[No Abstract] [Full Text] [Related]
25. Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Shaw AT; Solomon BJ
N Engl J Med; 2015 Feb; 372(7):683-4. PubMed ID: 25671264
[No Abstract] [Full Text] [Related]
26. [Crizotinib: At last in first-line treatment of advanced-stage ALK-rearranged non-small cell lung cancer].
Giroux Leprieur E; Wislez M
Bull Cancer; 2016 Feb; 103(2):125-6. PubMed ID: 26822904
[No Abstract] [Full Text] [Related]
27. Clinical relevance of ROS1 rearrangements detection in advanced squamous cell carcinomas.
Gibelin C; Avrillon V; De La Fouchardiere A; Mc Leer-Florin A; Lantuejoul S; Fayette J
Lung Cancer; 2016 Dec; 102():42-43. PubMed ID: 27987587
[TBL] [Abstract][Full Text] [Related]
28. Deepening the Knowledge of
Guaitoli G; Bertolini F; Bettelli S; Manfredini S; Maur M; Trudu L; Aramini B; Masciale V; Grisendi G; Dominici M; Barbieri F
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884672
[No Abstract] [Full Text] [Related]
29. ROS1 rearranged nonsmall cell lung cancer and crizotinib: An Indian experience.
Noronha V; Chandrakanth MV; Joshi AP; Patil V; Chougule A; Mahajan A; Janu AK; Chanana R; Prabhash K
Indian J Cancer; 2017; 54(2):436-438. PubMed ID: 29469073
[TBL] [Abstract][Full Text] [Related]
30. Clinical treatment patterns, molecular characteristics and survival outcomes of ROS1-rearranged non-small cell lung cancer: A large multicenter retrospective study.
Huang Z; Zhang Y; Xu Q; Song L; Li Y; Guo W; Lin S; Jiang W; Wang Z; Deng L; Qin H; Zhang X; Tong F; Zhang R; Liu Z; Zhang L; Yu J; Dong X; Gong Q; Deng J; Chen X; Wang J; Zhang G; Yang N; Zeng L; Zhang Y
Lung Cancer; 2024 Jun; 192():107827. PubMed ID: 38795459
[TBL] [Abstract][Full Text] [Related]
31. Crizotinib in the treatment of non--small-cell lung cancer.
Rothschild SI; Gautschi O
Clin Lung Cancer; 2013 Sep; 14(5):473-80. PubMed ID: 23790969
[TBL] [Abstract][Full Text] [Related]
32. Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer.
Kazandjian D; Blumenthal GM; Luo L; He K; Fran I; Lemery S; Pazdur R
Oncologist; 2016 Aug; 21(8):974-80. PubMed ID: 27328934
[TBL] [Abstract][Full Text] [Related]
33. Crizotinib inhibition of
Bebb DG; Agulnik J; Albadine R; Banerji S; Bigras G; Butts C; Couture C; Cutz JC; Desmeules P; Ionescu DN; Leighl NB; Melosky B; Morzycki W; Rashid-Kolvear F; Lab C; Sekhon HS; Smith AC; Stockley TL; Torlakovic E; Xu Z; Tsao MS
Curr Oncol; 2019 Aug; 26(4):e551-e557. PubMed ID: 31548824
[TBL] [Abstract][Full Text] [Related]
34. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
Michels S; Massutí B; Schildhaus HU; Franklin J; Sebastian M; Felip E; Grohé C; Rodriguez-Abreu D; Abdulla DSY; Bischoff H; Brandts C; Carcereny E; Corral J; Dingemans AC; Pereira E; Fassunke J; Fischer RN; Gardizi M; Heukamp L; Insa A; Kron A; Menon R; Persigehl T; Reck M; Riedel R; Rothschild SI; Scheel AH; Scheffler M; Schmalz P; Smit EF; Limburg M; Provencio M; Karachaliou N; Merkelbach-Bruse S; Hellmich M; Nogova L; Büttner R; Rosell R; Wolf J
J Thorac Oncol; 2019 Jul; 14(7):1266-1276. PubMed ID: 30978502
[TBL] [Abstract][Full Text] [Related]
35. Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer.
Roys A; Chang X; Liu Y; Xu X; Wu Y; Zuo D
Cancer Chemother Pharmacol; 2019 Oct; 84(4):679-688. PubMed ID: 31256210
[TBL] [Abstract][Full Text] [Related]
36. ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance.
Ye M; Zhang X; Li N; Zhang Y; Jing P; Chang N; Wu J; Ren X; Zhang J
Oncotarget; 2016 Mar; 7(11):12289-304. PubMed ID: 26802023
[TBL] [Abstract][Full Text] [Related]
37. [Clinical significance of ROS1 rearrangements in non-small cell lung cancer].
Xu L; Zhao R; Dong Z; Zhu T
Zhongguo Fei Ai Za Zhi; 2013 Dec; 16(12):663-70. PubMed ID: 24345493
[TBL] [Abstract][Full Text] [Related]
38. TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profiling.
Zhu VW; Upadhyay D; Schrock AB; Gowen K; Ali SM; Ou SH
Lung Cancer; 2016 Jul; 97():48-50. PubMed ID: 27237027
[TBL] [Abstract][Full Text] [Related]
39. Small cell transformation in crizotinib-resistant ROS1-rearranged non-small cell lung cancer with retention of ROS1 fusion: A case report.
Wu CH; Su PL; Hsu CW; Chu CY; Lin CC
Thorac Cancer; 2021 Nov; 12(22):3068-3071. PubMed ID: 34623764
[TBL] [Abstract][Full Text] [Related]
40. Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series.
Chiari R; Buttitta F; Iacono D; Bennati C; Metro G; Di Lorito A; Iezzi M; Tiseo M; Mazzoni F; Cappuzzo F; Marchetti A; Crinò L
Clin Lung Cancer; 2014 Nov; 15(6):470-4. PubMed ID: 25087901
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
